Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284213 | 0.86 | FFAR1 (0.39) | FFAR1FFAR4 | |
| SCHEMBL6285799 | 0.81 | GFER (0.46) | GFERFFAR1CASRMAPT | |
| SCHEMBL6285918 | 0.80 | HDAC1 (0.39) | GFERFFAR1FFAR4CASRMAPT | |
| SCHEMBL6279305 | 0.76 | LMNA (0.54) | GFERFFAR1FFAR4MAPT | |
| SCHEMBL10456914 | 0.73 | ESR2 (0.54) | FFAR1FFAR4CA2PTGER1PTGER4 | |
| Phenol SCHEMBL28213161 | 0.72 | PPARA (0.50) | FFAR1FFAR4PDCD1CD274PTGER1 | |
| SCHEMBL28638330 | 0.70 | ABL1 (0.54) | PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6279605 | 0.68 | PTGER1 (0.36) | GFERCASRPTGER1MAPT | |
| SCHEMBL27768912 | 0.67 | KEAP1 (0.60) | FFAR1FFAR4PDCD1CD274 | |
| SCHEMBL31489838 | 0.67 | DPP4 (0.56) | FFAR1FFAR4CA1CA2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | GFER 2720/4885FFAR1 2437/4885FFAR4 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.